Express Scripts to List Dariprim Alternative for $1

Express Scripts Holding, the biggest pharmacy benefits manager in the US, said it plans to list Imprimis Pharmaceuticals’ cheaper alternative to the toxoplasmosis treatment Daraprim (pyrimethamine) for $1 per pill.

Daraprim is being offered for $750 per pill by Turing Pharmaceuticals, which in August acquired marketing rights to the 62-year-old drug sold only in the US. The previous rights owner, Impax Laboratories, had sold it for $13.50 per pill.

After provoking outrage among doctors, patients and politicians – most prominently US presidential candidate Hillary Clinton – over the 50-fold hike, Turing later said it would reduce the price but did not disclose by how much or when this would take place.

Several other drugmakers have made headlines recently by purchased rights to old and cheap medicines that represent the only treatment for serious diseases and subsequently engaging in what is perceived by many as price gouging. Turing’s hike was especially controversial as toxoplasmosis mainly threatens people with weak immune systems, such as HIV and organ transplant patients, along with pregnant women.

The capsules provided by Imprimis, a young drug compounder based in San Diego, contain pyrimethamine and leucovorin. They will not require approval by the US Food and Drug Administration as the ingredients are already approved. Like the sulfonamide used with Daraprim, the California firm will use leucovorin to limit pyrimethamine's side effects.

Leaders of the US HIV Medicine Association and The Infectious Diseases Society of America have urged other pharmacy benefits managers and health insurers to make the Imprimis option available, saying care providers have faced "significant challenges" in obtaining the treatment for patients since Turing raised the price.

Express Scripts, which manages prescription drug benefits for about 85 million people, has repeatedly criticized price gouging. Last year, it waded into the debate over the high cost of hepatitis C treatments by choosing AbbVie's Viekira Pak over more expensive drugs produced by Sovaldi and Harvoni. Subsequently it won a hefty price reduction from the latter two companies.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.